Xu Zhe, Fan Jin, Luo Xin, Zhang Wen-Bo, Ma Jun, Lin Yu-Bi, Ma Shao-Hong, Chen Xin, Wang Zhi-Ping, Ou Jing-Song, Zhang Xi
Division of Cardiac Surgery, The First Affiliated Hospital of Sun-Yat-sen University, Guangdong, PR China.
Division of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, PR China.
Can J Cardiol. 2016 Oct;32(10):1248.e1-1248.e9. doi: 10.1016/j.cjca.2015.11.005. Epub 2015 Nov 12.
Managing anticoagulation in pregnant women with mechanical heart valves remains challenging. Our aim was to evaluate the effectiveness and safety of 4 regimens in these women.
Relevant studies published before June 2015 were collected in several databases and analyzed with RevMan version 5.3 and SPSS version 19.0. Four regimens were defined as follows: a regimen of a vitamin K antagonist (VKA) throughout pregnancy; a heparin (H)/VKA regimen using VKAs except for unfractionated heparin (UFH) or low molecular weight heparin (LMWH) during 6-12 weeks of pregnancy; a LMWH regimen of adjusted LMWH doses throughout pregnancy; and a UFH regimen of adjusted UFH doses throughout pregnancy. The low warfarin dose in the VKA regimen was defined as 5 mg/d or less.
Fifty-one studies comprising 2113 pregnancies in 1538 women were included. The rate of fetal wastage was significantly higher in the high warfarin dose subgroup than in the low dose one. Compared with the H/VKA regimen, the rate of maternal major thromboembolic event in the low-dose VKA regimen group was significantly lower, although the fetal outcomes were similar. Compared with the H/VKA regimen, the rate of fetal wastage in the LMWH regimen group was significantly lower, and the maternal outcomes were similar. The UFH regimen presented the worst maternal and fetal outcomes.
In the absence of large prospective trials, this meta-analysis showed that the VKA regimen should be best for pregnant women with a low warfarin dose, and the H/VKA regimen might be reasonable for those with a high warfarin dose. The LMWH regimen could be used for those who refuse VKA.
对于患有机械心脏瓣膜的孕妇进行抗凝管理仍然具有挑战性。我们的目的是评估这4种方案在这些女性中的有效性和安全性。
收集2015年6月之前在多个数据库中发表的相关研究,并使用RevMan 5.3版和SPSS 19.0版进行分析。4种方案定义如下:整个孕期使用维生素K拮抗剂(VKA)的方案;在妊娠6 - 12周期间使用除普通肝素(UFH)或低分子肝素(LMWH)外的VKA的肝素(H)/VKA方案;整个孕期调整LMWH剂量的LMWH方案;以及整个孕期调整UFH剂量的UFH方案。VKA方案中的低华法林剂量定义为5毫克/天或更低。
纳入了51项研究,涉及1538名女性的2113次妊娠。高华法林剂量亚组的胎儿流产率显著高于低剂量亚组。与H/VKA方案相比,低剂量VKA方案组的母亲主要血栓栓塞事件发生率显著更低,尽管胎儿结局相似。与H/VKA方案相比,LMWH方案组的胎儿流产率显著更低,母亲结局相似。UFH方案的母亲和胎儿结局最差。
在缺乏大型前瞻性试验的情况下,这项荟萃分析表明,低华法林剂量的VKA方案对孕妇可能是最佳选择,高华法林剂量的孕妇采用H/VKA方案可能是合理的。LMWH方案可用于拒绝VKA的患者。